Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
A representative of Japan’s pharmacist association on March 12 reiterated his call for the packaging units of expensive drugs to be aligned to actual clinical use, urging the regulator to consider some kind of pricing measures such as price reductions…
To read the full story
Related Article
- Pharmacies Reel from Pricey Drug Waste, Sparking Calls for Packaging Overhaul and Price Penalties
August 27, 2025
- Japan to Survey Drug Waste at Pharmacies amid Rising Concerns Over Disposal Costs
July 11, 2025
- At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
- Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
March 13, 2025
- JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
REGULATORY
- Chuikyo OKs NHI Listing for Cuorips’ iPSC-Based Riheart
July 23, 2026
- Japan Moves to Bar Duplicate IRB Reviews under Single-IRB Framework
July 23, 2026
- Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
- Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
- Japan Backs Calquence-Venclexta Regimen for Untreated CLL via Label Updates
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…